Bleomycin is widely used as an off-label treatment for various dermatologic indications. However, a much-needed critical appraisal of the currently available evidence is lacking. We therefore evaluated the quality of clinical evidence for the efficacy and safety of intralesional bleomycin treatment for dermatologic indications with the aim to provide evidence-based recommendations for clinical practice. The PubMed, Embase, Medline Ovid, Web of Science, Cochrane Central, and Google Scholar databases were systematically searched. Two authors independently selected relevant studies according to predefined inclusion and exclusion criteria. We assessed the methodologic quality with the Cochrane Collaboration risk-of-bias assessment tool and selected 10 randomized clinical trials and 15 clinical controlled trials. Treatment indications included common warts, nonmelanoma skin cancer, cutaneous metastases, keloid and hypertrophic scars, and hemangioma. Intralesional bleomycin treatment showed significantly higher cure rates for warts compared with other treatments. Local adverse events included erythema, blackening, eschar formation, and superficial ulceration. None of the studies reported systemic adverse events. Methodologic quality of the studies was generally low. Consequently, no firm recommendations can be made for intralesional bleomycin treatment in clinical practice. However, this review suggests that intralesional bleomycin is a successful and well-tolerated treatment for recalcitrant warts.

bleomycin, cutaneous metastases, dermatology, drug response, efficacy, electrochemotherapy, hemangioma, hypertrophic scars, intralesional, keloid, nonmelanoma skin cancer, safety, systematic review,
American Academy of Dermatology. Journal
Department of Dermatology

Bik, L. (Liora), Sangers, T. (Tobias), Greveling, K, Prens, E.P, Haedersdal, M. (Merete), & van Doorn, M.B.A. (2020). Efficacy and tolerability of intralesional bleomycin in dermatology: A systematic review. American Academy of Dermatology. Journal. doi:10.1016/j.jaad.2020.02.018